1-6 of 6
Todd Covey, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Variable Bruton Tyrosine Kinase (BTK) Resynthesis across Patients with Chronic Lymphocytic Leukemia (CLL) on Acalabrutinib Therapy Affect Target Occupancy and Reactivation of B-Cell Receptor (BCR) Signaling

Free
Anfal A. Alsadhan, Jean Cheung, Michael Gulrajani, Erika M. Cook, Stefania Pittaluga, MD PhD, Theresa Davies-Hill, Raquel Izumi, PhD, Clare C. Sun, MD, Todd Covey, PhD, Adrian Wiestner, MD, Sarah E. M. Herman, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4401.
https://doi.org/10.1182/blood-2018-99-110391
Published: 2018
Journal Articles

Acalabrutinib in Patients with Relapsed/Refractory (R/R) and High-Risk, Treatment-Naive (TN) Chronic Lymphocytic Leukemia (CLL)

Free
Clare C. Sun, MD, Pia Nierman, RN, Inhye E. Ahn, MD, Janet Valdez, Jennifer Lotter, Susan Soto, Sarah E. M. Herman, PhD, Todd Covey, PhD, Ahmed Hamdy, MD, Raquel Izumi, PhD, Dongmei Liu, PhD, Priti Patel, MD, Adrian Wiestner, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4424.
https://doi.org/10.1182/blood-2018-99-110395
Published: 2018
Journal Articles

Potency and Selectivity of BTK Inhibitors in Clinical Development for B-Cell Malignancies

Free
Allard Kaptein, Gerjan de Bruin, Maaike Emmelot-van Hoek, Bas van de Kar, Anouk de Jong, Michael Gulrajani, Dennis Demont, Todd Covey, PhD, Diana Mittag, Tjeerd Barf
Journal: Blood
Blood (2018) 132 (Supplement 1): 1871.
https://doi.org/10.1182/blood-2018-99-109973
Published: 2018
Journal Articles

Pharmacodynamic Evaluation of Acalabrutinib in Relapsed/Refractory and Treatment-Naive Patients with Chronic Lymphocytic Leukemia (CLL) in the Phase 1/2 ACE-CL-001 Study

Free
Todd Covey, PhD, Michael Gulranjani, Jean Cheung, Elena Bibikova, Tracy Clevenger, Fanny Krantz, Karen Pan, Kyoko Yamaguchi, Anouk De Jong, Bart Van Lith, Diana Mittag, Raquel Izumi, PhD, John C. Byrd, MD, William G Wierda, MD PhD, Susan M. O'Brien, MD, Richard R. Furman, MD, Allard Kaptein, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1741.
https://doi.org/10.1182/blood.V130.Suppl_1.1741.1741
Published: 2017
Journal Articles

Efficacy and Safety of Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Mantle Cell Lymphoma in the Phase 2 ACE-LY-004 Study

Free
Michael Wang, MD, Simon Rule, MD, Pier Luigi Zinzani, MD PhD, Andre Goy, MD, Rene-Olivier Casasnovas, MD, Stephen D. Smith, MD, Gandhi Damaj, MD, Jeanette K. Doorduijn, MD PhD, Thierry Lamy, Pr, MD PhD, Franck Morschhauser, MD PhD, Carlos Panizo, MD PhD, Bijal Shah, MD, Andrew Davies, PhD, Richard Eek, MBCHB, Jehan Dupuis, MD, Eric Jacobsen, MD, Arnon P. Kater, MD PhD, Steven Le Gouill, MDPhD, Lucie Oberic, MD, Tadeusz Robak, MD PhD, Todd Covey, PhD, Richa Dua, PharmD, Ahmed Hamdy, MD, Xin Huang, Raquel Izumi, PhD, Priti Patel, MD, J. Greg Slatter, PhD, Wojciech Jurczak, PhDMD
Journal: Blood
Blood (2017) 130 (Supplement 1): 155.
https://doi.org/10.1182/blood.V130.Suppl_1.155.155
Published: 2017
Journal Articles

Acalabrutinib with Obinutuzumab in Relapsed/Refractory and Treatment-Naive Patients with Chronic Lymphocytic Leukemia: The Phase 1b/2 ACE-CL-003 Study

Free
Jennifer A. Woyach, MD, Farrukh T. Awan, MD MS, Mojgan Jianfar, MD, Kerry A. Rogers, MD, Jeffrey Jones, MD MPH, Todd Covey, PhD, Ahmed Hamdy, MD, Raquel Izumi, PhD, Priti Patel, MD, Min Hui Wang, PhD, John C. Byrd, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 432.
https://doi.org/10.1182/blood.V130.Suppl_1.432.432
Published: 2017